SCHEMBL6450101

SCHEMBL6450101

ON=Cc1cc(Cl)cc(Cl)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.59
MEN1 O00255 12/20 0.57
KMT2A Q03164 12/20 0.57
MAPT P10636 8/20 0.57
ALDH1A1 P00352 6/20 0.57
KDM4E B2RXH2 6/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CYP3A4 P08684 1/20 0.52
TSHR P16473 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
POLB P06746 3/20 0.49
NPC1 O15118 2/20 0.49
MITF O75030 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450098 1.00 ERN1 (0.59) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL17750101 0.83 MEN1 (0.41) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL2697239 0.82 ERN1 (0.57) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL3085646 0.81 ALDH1A1 (0.46) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL3085648 0.81 ALDH1A1 (0.46) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL2222204 0.80 CA12 (0.58) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL16080725 0.79 MEN1 (0.71) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL10567385 0.78 HPGD (0.44) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL13639930 0.77 MEN1 (0.79) ERN1MEN1KMT2AMAPTALDH1A1
SCHEMBL11245961 0.76 MAPT (0.56) ERN1MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC ERN1 1272/4885MEN1 3473/4885KMT2A 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.